Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 13/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24787659 | 1.00 | ADORA2B (0.63) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL30073541 | 0.94 | ADORA2B (0.72) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL24787320 | 0.94 | ADORA2B (0.72) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL30073364 | 0.94 | ADORA2B (0.72) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL1001096 | 0.93 | ADORA2B (0.67) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL1497273 | 0.85 | ADORA2B (0.66) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL1497283 | 0.85 | ADORA2B (0.70) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497252 | 0.83 | ADORA2B (0.66) | ADORA2BADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL30682457 | 0.83 | ADORA2B (0.70) | ADORA2BADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL30682506 | 0.83 | ADORA2B (0.70) | ADORA2BADORA2AADORA1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117337263-A | As A 2 Cyclic amide containing pyridylxanthines as B antagonists | 阿多维特有限责任公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as A2B antagonists | ADOVATE, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220402919-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADOVATE, LLC | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402919-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as A2B antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.